Salmonella Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: January 20, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
CAGR |
7.3% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Product, End user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
The global Salmonella treatment market is expected to register a revenue CAGR of 7.3% during the forecast period from 2022 to 2030.
Salmonella Treatment Market Fundamentals
Salmonella is rod-shaped (bacillus) Gram-negative bacterium that belongs to the Enterobacteriaceae family. Certain serotypes of the intracellular pathogen Salmonella species can cause disease. Most diseases are transmitted due to eating food that has been contaminated by either human or animal excrement.
Salmonellosis, a common infectious disease that affects the gastrointestinal tract, is caused by Salmonella. In this disorder, an individual may experience stomach (abdominal) cramps, fever, and diarrhea between 8 to 72 hours of exposure. Majority of healthy individuals recover without a need for special care after a few days to a week of the infection. Diarrhea can occasionally result in severe dehydration, which calls for immediate medical care. Life-threatening problems may arise if the infection leaves the intestine.
Traveling to countries with unclean drinking water and improper sewage disposal increases the possibility of contracting Salmonella. Salmonellosis is more likely to affect people who reside or work close to high-risk animals, such as chickens, ducks, turtles, and lizards. Additionally, possibilities of disease transmission increase among individuals using antacids or antibiotics. The population under the age of 12 months and above 65 years are at higher risk of acquiring the infection easily. Furthermore, having inflammatory bowel illness, a compromised immune system, or sickle cell disease may increase the risk of infection and subsequent complications.
Rest and rehydration are the sole treatments for nontyphoidal Salmonella; however, antibiotics are used to treat enteric fever and complex Salmonella infections. Loperamide (Imodium A-D) can ease the cramping associated with diarrhea. Antibiotics, such as ciprofloxacin, azithromycin, are recommended by a doctor to remove the bacteria.
Salmonella Treatment Market Dynamics
Increase in awareness among people about Salmonella infection and rise in the number of food-borne illnesses are expected to fuel the revenue growth in the global market for Salmonella treatment during the forecast period.
Salmonella infections are more likely to occur in young children under the age of 5 to 12 and older people (65 years and above) with weakened immunity. Thus, growth in this population base is responsible for the high demand for different treatments to combat Salmonella infection.
Increased prevalence of several gastrointestinal and food-borne diseases are crucial factors behind the emergence of Salmonella outbreaks. According to WHO, contaminated food contributes to 420,000 fatalities and 600 million incidences of food-borne illnesses worldwide each year. Moreover, consuming unhealthy food results in the loss of 33 million people worldwide. On the other hand, adoption of unhealthy lifestyles, such as alcohol consumption, stress, and low fiber diet, has resulted in rise in the cases of various kinds of gastrointestinal diseases. Moreover, rise in the usage of multiple antibiotics in treatment has resulted into the development of salmonellosis for immune compromission. These factors are expected to drive revenue growth in the Salmonella treatment market during the forecast period.
However, absence of developed infrastructure and resources for food control in developing countries is likely to hamper the revenue growth of the global Salmonella treatment market. Also, antimicrobial resistance to Salmonella has become a major public health concern in the recent few years. Thus, high prevalence of drug-resistant forms of Salmonella is expected to restrain the revenue growth of the market.
Salmonella Treatment Market Ecosystem
The global Salmonella treatment market is analyzed from three perspectives: product, end-user, and region.
Salmonella Treatment Market by Product
[9740239]
Based on the product, the global Salmonella treatment market is segmented into antibiotics, vaccines, and others.
The antibiotics segment accounted for the largest revenue share of the market. The antibiotic segment is further sub-segmented into cephalosporin, ciprofloxacin, azithromycin, and others.
A third-generation cephalosporin, such as ceftriaxone, is the first antibiotic to be used in cases where salmonellosis is presumed but not confirmed. Ciprofloxacin, azithromycin, or ceftriaxone are the preferable antibiotics if a complex Salmonella infection or typhoid fever has been identified. Treatment with antibiotics is advised for seriously unwell patients, along with fluids. Administration of antibiotics is suggested for severely dehydrated individuals or for people with mild dehydration with ongoing net fluid loss upon rehydration to help minimize resource requirements. Antibiotics speed up recovery and shorten hospital stays by reducing the frequency and volume of diarrhea and stools, which both help make better use of resources during an outbreak. Also, it is advised for patients who are receiving rehydration therapy but are still passing a lot of stools due to severe or mild dehydration. Additionally, comorbid patients and pregnant women are advised to have antibiotic treatment. On the other hand, different antibiotics are cost-effective as well as easily available in nearby pharmacies in an emergency and as a first state of treatment. Moreover, launch of antibiotics for better treatment and increase in the R&D activities by players are supporting the segment’s revenue growth.
Salmonella Treatment Market by End-user
Based on the end-user, the global Salmonella treatment market is segmented into hospitals, clinics, and others.
The hospitals segment accounted for the highest CAGR in 2021. Most people who contract Salmonella recover entirely without medical intervention. However, occasionally the illness can be severe enough to necessitate hospitalization. Thus, rise in the number of hospitalizations is expected to fuel revenue growth in the hospitals segment during the forecast period.
Salmonella Treatment Market by Region
Based on the region, the global Salmonella treatment market is segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America accounts for the largest revenue share of the market. This can be attributed to rise in the patient pool suffering from food poisoning. For instance, the CDC estimates that each year in the U.S., Salmonella bacteria are responsible for around 1.35 million infections, 26,500 hospitalizations, and 420 fatalities. The presence of advanced R&D facilities and significant investments by major companies in the development of effectual treatments are expected to accelerate the growth of the target market. Furthermore, expanding food sector and increased public awareness of illnesses spread through food and water are propelling the Salmonella treatment market in North America. Increase in adoption of international standards for food safety, as well as technological advancements in bacterial detection technologies, are also contributing to the expansion of this market.
The market in Asia Pacific is expected to register revenue growth at the highest pace during the forecast period. This can be ascribed to rising government spending on the development of advanced hospital facilities to offer better patient care and increasing R&D activities by private and public players in this region. In addition, supportive business regulations and emergence of mid-size businesses with creative solutions are projected to propel the regional market expansion in the next few years.
Salmonella Treatment Market Competitive Landscape
The prominent companies operating the global Salmonella treatment market are:
Salmonella Treatment Market Strategic Developments
Salmonella is the causative agent of salmonellosis, a typical gastrointestinal infection. Loperamide (Imodium A-D), a medication, can ease the discomfort associated with diarrhea. Antibiotics and vaccines are usually used to eradicate the bacteria.
Increasing prevalence of food-borne infections, inappropriate hygiene practice, improving vaccine development activities, and rising disease awareness are driving revenue growth in the global Salmonella treatment market.
GlaxoSmithKline, Hardy Diagnostics, Eiken Chemical Company Limited, Sanofi Pasteur SA, and Pfizer are among the key companies operating in the global Salmonella treatment market.
Lack of awareness and absence of developed infrastructure and resources for food control in developing countries are restraining the revenue growth of the global Salmonella treatment market.
The global Salmonella treatment market is expected to register a revenue CAGR of 7.3% during the forecast period from 2022 to 2030.
*Insights on financial performance are subject to the availability of information in the public domain